Navigation Links
Vitamin D supplementation may delay precocious puberty in girls
Date:6/17/2013

of precocious puberty using vitamin D or related molecules," said study lead author Min Sun Kim, MD, PhD, assistant professor at Chonbuk National University Medical School in Jeonju, South Korea. "Our results suggest that vitamin D may inhibit early pubertal onset and/or the rapid progression of puberty, at least in part, through the suppression of NMDA-mediated GnRH neuronal excitation in humans."

Study participants included 110 girls between the ages of 7 to 10 years. Seventy-five girls exhibited normal patterns of development, while 35 were classified as having precocious puberty. Investigators used the Tanner scale, which assesses human physical development, to differentiate normal versus precocious pubertal development.

According to Kim, more research, including studies in animal models, is necessary to confirm this project's findings.


'/>"/>

Contact: Jenni Glenn Gingery
jgingery@endocrine.org
301-941-0240
The Endocrine Society
Source:Eurekalert

Page: 1 2

Related biology news :

1. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
2. Vitamin D supplements may protect against viral infections during the winter
3. Vitamin D for pregnant women and babies -- how much is enough?
4. Collaborative research team identifies safe upper level for vitamin A consumption for puppies
5. Health benefits of vitamin D dependent on type taken
6. Vitamin D with calcium shown to reduce mortality in elderly
7. 15th Vitamin D Workshop begins tomorrow
8. Link between vitamin C and twins can increase seed production in crops
9. Low vitamin D levels linked to weight gain in some older women
10. Obesity plus low vitamin D may add up to a greater risk of diabetes
11. Scientists confirm existence of vitamin deserts in the ocean
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Earth,s history has been going on for hundreds of millions of ... existed, scientists reported today in the journal Nature . ... organism in the oceans, survives where most other cells would die ... had been theorized that SAR11 was so small and widespread that ...
... University of Alberta study shows that busy beavers are helping Canada ... begin spring nesting. Ponds in Alberta where beavers were active ... geese a better chance at reproductive success, according to the study, ... the first to link beavers to early season nesting habits of ...
... the NSERC Canadian Network for Aquatic Ecosystems (CNAES) will ... made when it comes to this country,s wetlands, lakes ... from the Natural Sciences and Engineering Research Council, in ... organizations, was recently announced as part of the government,s ...
Cached Biology News:A war without end -- with Earth's carbon cycle held in the balance 2Canada's aquatic ecosystems research gets boost from NSERC 2
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 A new ... it easier for research institutions to learn how Appleā€™s ... data. , The timing is ideal since Apple made ... Research Kit is an open-source framework for developing medical ... provides a way for researchers to collect secure clinical ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, today ... has been added as a clinical trial site for ... patients with refractory glioblastoma multiforme (GBM), the most common ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... GNVC ) today announced its financial results for the third ... $3.6 million ($0.04 per share) for the three months ended September ... per share) in the comparable quarter of 2008. For the nine ... ($0.15 per share), compared to a net loss of $19.6 million ...
... Conference Call on Thursday, November 5, 2009 at 4:30 ... 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the ... results for the third quarter and nine months ended ... the third quarter of 2009. , The following consolidated ...
... DIEGO, CA, November 5, 2009 Senomyx, Inc. (Nasdaq: ... technologies to discover novel flavor ingredients for the food, beverage, ... reported financial results for the third quarter ended September 30, ... of 2009, compared to $4.0 million for the third quarter ...
Cached Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
...
Biology Products: